Feasibility study of dose-dense biweekly administered pemetrexed in patients with non-small cell lung cancer.
Abstract BACKGROUND AND OBJECTIVES: Pemetrexed is a multitargeted folate pathway inhibitor with documented activity in non-small cell lung cancer (NSCLC). …